• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Illumina

Illumina

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. ILMN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Illumina , Inc. and a Lead Plaintiff Deadline of February 14, 2017

    ILMN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Illumina , Inc. and a Lead Plaintiff Deadline of February 14, 2017

  2. Illumina Debuts VeriSeq™ Analysis Software (48 Samples), Optimized Data Analysis for Noninvasive Prenatal Testing

    Illumina Debuts VeriSeq™ Analysis Software (48 Samples), Optimized Data Analysis for Noninvasive Prenatal Testing

  3. Bioinformatics Market 2015-2022: Software, Hardware, and Biocontent - Global Strategic Business Report 2017 - Research and Markets

    Bioinformatics Market 2015-2022: Software, Hardware, and Biocontent - Global Strategic Business Report 2017 - Research and Markets

  4. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Illumina , Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017

    INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Illumina , Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017

  5. UPDATE: 10 best, 10 worst U.S. stocks in January

    UPDATE: 10 best, 10 worst U.S. stocks in January

  6. 10 best, 10 worst U.S. stocks in January

    10 best, 10 worst U.S. stocks in January

  7. Global Single Cell Analysis Market Analysis & Trends 2017 - Industry Forecast to 2025 - Research and Markets

    Global Single Cell Analysis Market Analysis & Trends 2017 - Industry Forecast to 2025 - Research and Markets

  8. Tuttle Tactical Management Weekly Market Notes

    Illumina ILMN reported second-quarter results Tuesday that beat our expectations, and we plan to raise our fair value estimate by several dollars per share. Revenue totaled $84.5 million for the quarter, a 103% increase from the year-ago period, which prompted the firm to significantly raise its ...

  9. Leader in Genomic Sequencing Illuminates the Way

    Continued technology advancements and market expansion support Illumina's narrow moat.

  10. 3 Big Moat Rating Changes From 2014

    Competitive advantages have improved for Mead Johnson, while De La Rue's moat was downgraded to narrow and POSCO was deemed a no-moat company.

12

©2017 Morningstar Advisor. All right reserved.